Innova Medical Group confirms its rapid and cost-effective
Lateral Flow Tests detect emergent mutations
PASADENA, Calif., Dec. 6, 2021 /PRNewswire/ -- Innova Medical
Group, Inc., a global health screening and diagnostic innovator and
the world's largest manufacturer and distributor of lateral flow
test kits, has confirmed that the company's SARS-CoV-2 Antigen
Tests detect the Omicron variant.
A WHO variant of concern, the strain has become more widespread
around the world in recent weeks, with dozens of cases detected in
the UK.
In response to the variant's emergence, government measures
brought into effect this week have reimposed compulsory
mask-wearing in England in shops
and on public transport.
While researchers are working diligently to determine the
efficacy of vaccines and boosters against the new variant, rapid
testing is a critically important tool in effectively controlling
the spread of the virus and help keep communities safe. Innova has
confirmed its Lateral Flow Tests are effective in detecting the
B.1.1.529 (Omicron) variant.
Innova started assessing the variant after it was published by
the WHO in late-November and the results were additionally
confirmed in other laboratories.
"As the Omicron strain shows signs of increased transmissibility
across the world, the global effort to eliminate COVID-19 requires
frequent, comprehensive and equitable testing that can rapidly
detect these emerging strains," said Daniel
Elliott, President and CEO of Innova Medical
Group.
Numerous scientific studies as well as ongoing public health
screening of millions of people on a regular basis have shown rapid
antigen tests are an important tool for identifying infectious
people quickly and equitably, even when they may not have symptoms
of COVID-19, in ways that simply are not possible with slower, more
expensive, lab-based tests. This has become even more important
following initial suggestions Omicron variant symptoms can be
milder in some people than other strains.
While the virus continues to morph its genetic ribonucleic acid
("RNA") to generate new and potentially more contagious or more
harmful variants, Innova's antigen test, which detects multiple
proteins in the virus, can often be a more effective tool in
controlling the spread and reducing surges than other methods, such
as PCR testing.
"We're proud to supply our partners around the world with
cost-effective, readily available tests which can successfully
detect the spread of multiple strains of the virus and ultimately
play a major role in assisting the global health community in
stamping out this pandemic," added Mr. Elliott.
When coupled with Innova's expansive production capacity, the
wide-ranging detection capabilities of Innova's rapid antigen
tests, which have been widely distributed by
the government across the UK in a variety of use cases for
over a year now, underline Innova's role as a critical partner to
nations and businesses alike in containing the more contagious
strains.
For more information on Innova, please
visit: https://www.innovamedgroup.com
About Innova Medical Group, Inc.
Innova Medical Group, wholly owned by Pasaca Capital, Inc., is a
global health screening and diagnostic innovator driven to
dramatically improve health outcomes worldwide with equitable,
high-value testing solutions. From delivering more than 2 billion
COVID-19 rapid test kits to customers worldwide since the beginning
of the pandemic, to providing critical vaccines, including highly
sought-after WHO approved COVID-19 vaccines to the world
population, Innova is committed to improving the human condition
globally. Our strategic and iterative approach enables us to
create, build and deploy a myriad of accessible tests customized to
meet and empower the user at their point of need. With a panoramic
vision spanning the present to the future, we develop trusted
solutions that are both intuitive and secure to use. We quickly and
nimbly became the world's largest provider of COVID-19 tests, and
we are determined to execute on this model across infectious
disease, other chronic conditions and wellness. For more
information, please visit: www.innovamedgroup.com
Logo -
https://mma.prnewswire.com/media/1494814/Innova_tagline_blue_Logo.jpg